Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
Go back to Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes| (NASDAQ: PGEN) | Delayed: 6.87 -0.23 (3.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.10 | 52 Week High | $ | |||
| Open | $6.89 | 52 Week Low | $ | |||
| Day High | $7.02 | P/E | N/A | |||
| Day Low | $6.72 | EPS | $ | |||
| Volume | 2,764,016 | |||||
